Introducing a unique and interactive SLAS event focused on 'Omics, Synthetic Biology and Genome Editing along with applicable implications for the current pandemic. Join us June 23-24, 2020, for 30-minute scientific research presentations, followed by live exhibitor presentations and one-on-one networking including participation incentives for attendees!
Get your All Access Pass today, plus a chance to win a free registration to SLAS events in 2021!
Scientific Program Organizers
Sammy Datwani, Ph.D., Consultant, SLAS Board Member
Zack Gurard-Levin, Ph.D., SAMDI Tech Inc.
Ira Hoffman, CEO, High-Res Biosolutions, SLAS Board Member
Ash Jogalekar, Ph.D., Strateos
Scientific sessions will alternate with vendor tutorials and dedicated exhibition engagement time (well beyond your typical chat window). The event will be presented within an easy-to-navigate, interactive platform, which allows for simultaneous small group video chat or one-on-one on-demand networking all day. Invite your colleagues from around the world -- morning, afternoon, and early evening sessions will be available each day.
The SLAS event platform will provide a truly integrated exhibition experience for technology providers. No avatars or fake plants in our exhibit hall. Exhibitors: you are invited to demo a new or existing product, take questions, set up one-on-one video meetings with attendees, organize follow-up conversations or small group chat sessions after your presentation. Think of this as your new remote office with customers stopping by. No masks necessary and social distancing guidelines are guaranteed.
Not ready to present a demo or tutorial but want to get out in front of the SLAS community? Sponsorship opportunities will also be available for a variety of platform features, paricipant giveaways and more.
In vivo Delivery of Nucleic Acids, Genome Editing Tools and Cells
Daniel Anderson, Ph.D.
Professor of Chemical Engineering, Institute for Medical Engineering and Science & Koch Institute, MIT
Detection of SARS-CoV-2 with the CRISPR-based DETECTR Platform
Janice Chen, Ph.D.
Co-founder and Chief Technology Officer, Mammoth Biosciences
Synthetic Biology -- Biology by Design
Jim Collins, Ph.D.
Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering, MIT
Drug Repurposing for COVID-19 and the NCATS OpenData Portal Matt Hall, Ph.D.
Acting Branch Chief, National Center for Advancing Translational Science
Applying AI to Accelerate Assay Development to Pandemic Speed
Imran Haque, Ph.D.
VP of Data Science, Recursion Pharmaceuticals
Testing Multiple Approaches to Decrease Sequencing Costs and Efficiently Distribute Sequencing Reads for Simultaneous Protein and mRNA Quantification at the Single Cell Level
Stefanie Mortimer, Ph.D.
Senior Director, BD Biosciences
Presentation title to come. Allen Northrup, Ph.D.
Northrup Consulting Group
Developing a New Class of Cell Therapies at the Intersection of Synthetic Biology and Genome Engineering
Marcin Paduch, Ph.D.
Director of Technology Development, ArsenalBio
Kyle Siebenthall, Ph.D.
Platform Development Scientist, ArsenalBio
Vignettes of the COVID-19 Crisis Driving Sequencing Innovation Keith Robison, Ph.D.
Principal Engineer, Ginkgo Bioworks
Identifying Regional Outbreak and Spread of COVID-19 from Population-wide Surveys
Eran Segal, Ph.D.
Professor, Department of Computer Science, Weizmann Institute of Science
A Fully Automated Platform to Detect On-Target CRISPR/Cas9 Genome Editing Olga Seltser, Ph.D.
Associate Director of Automation, Intellia Therapeutics Ross Lagoy, Ph.D.
Automation Engineer, Intellia Therapeutics
Ultrasensitive Protein Assays for the COVID-19 Pandemic
David Walt, Ph.D.
Hansjörg Wyss Professor of Bioinspired Engineering, Harvard Medical School,
Professor of Pathology, Harvard Medical School and Brigham and Women’s Hospital
